HRP20151018T1 - Pirolopiridini kao inhibitori kinaze - Google Patents

Pirolopiridini kao inhibitori kinaze Download PDF

Info

Publication number: HRP20151018T1
Authority: HR; Croatia
Prior art keywords: image; alkyl; hydrogen; compound according; pharmaceutically acceptable
Prior art date: 2008-05-13

Application number

HRP20151018TT

Other languages

English (en)

Croatian (hr)

Inventor

Yvan Le Huerou

James F. Blake

Indrani W. Gunwardana

Peter J. Mohr

Eli M. Wallace

Bin Wang

Mark Chicarelli

Michael Lyon

Original Assignee

Array Biopharma, Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-05-13

Filing date

2015-09-28

Publication date

2015-10-23

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40810786&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20151018(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2015-09-28 Application filed by Array Biopharma, Inc. filed Critical Array Biopharma, Inc.

2015-10-23 Publication of HRP20151018T1 publication Critical patent/HRP20151018T1/hr

Links

229940043355 kinase inhibitor Drugs 0.000 title 1
239000003757 phosphotransferase inhibitor Substances 0.000 title 1
150000005255 pyrrolopyridines Chemical class 0.000 title 1
-1 -SO2R1 Chemical group 0.000 claims 34
150000001875 compounds Chemical class 0.000 claims 22
229910052739 hydrogen Inorganic materials 0.000 claims 20
239000001257 hydrogen Substances 0.000 claims 20
125000004435 hydrogen atom Chemical group [H]* 0.000 claims 16
150000003839 salts Chemical class 0.000 claims 11
125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 9
125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 9
125000004429 atom Chemical group 0.000 claims 9
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 9
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 6
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 5
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
125000003118 aryl group Chemical group 0.000 claims 4
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 4
229910052736 halogen Inorganic materials 0.000 claims 4
150000002367 halogens Chemical group 0.000 claims 4
125000000623 heterocyclic group Chemical group 0.000 claims 4
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 4
125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 3
125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims 3
125000001072 heteroaryl group Chemical group 0.000 claims 3
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 3
125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 2
125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims 2
125000000217 alkyl group Chemical group 0.000 claims 2
125000000753 cycloalkyl group Chemical group 0.000 claims 2
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 2
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 2
229920006395 saturated elastomer Polymers 0.000 claims 2
125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
125000006727 (C1-C6) alkenyl group Chemical group 0.000 claims 1
125000006432 1-methyl cyclopropyl group Chemical group [H]C([H])([H])C1(*)C([H])([H])C1([H])[H] 0.000 claims 1
125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims 1
125000001847 2-phenylcyclopropyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C1([H])C([H])([H])C1([H])* 0.000 claims 1
125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 claims 1
125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 claims 1
125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 1
125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 1
125000003342 alkenyl group Chemical group 0.000 claims 1
125000004566 azetidin-1-yl group Chemical group N1(CCC1)* 0.000 claims 1
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
125000002618 bicyclic heterocycle group Chemical group 0.000 claims 1
229910052794 bromium Inorganic materials 0.000 claims 1
229910052801 chlorine Inorganic materials 0.000 claims 1
125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
125000005745 ethoxymethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])* 0.000 claims 1
125000004705 ethylthio group Chemical group C(C)S* 0.000 claims 1
229910052731 fluorine Inorganic materials 0.000 claims 1
UHCBBWUQDAVSMS-UHFFFAOYSA-N fluoroethane Chemical group CCF UHCBBWUQDAVSMS-UHFFFAOYSA-N 0.000 claims 1
125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 claims 1
125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 claims 1
125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 claims 1
125000004312 morpholin-2-yl group Chemical group [H]N1C([H])([H])C([H])([H])OC([H])(*)C1([H])[H] 0.000 claims 1
125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 claims 1
239000000825 pharmaceutical preparation Substances 0.000 claims 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 claims 1
125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 claims 1
125000004262 quinoxalin-2-yl group Chemical group [H]C1=NC2=C([H])C([H])=C([H])C([H])=C2N=C1* 0.000 claims 1
125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
239000000126 substance Substances 0.000 claims 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
125000004192 tetrahydrofuran-2-yl group Chemical group [H]C1([H])OC([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
238000002560 therapeutic procedure Methods 0.000 claims 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

HRP20151018TT 2008-05-13 2015-09-28 Pirolopiridini kao inhibitori kinaze HRP20151018T1 (hr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US5292608P	2008-05-13	2008-05-13
PCT/US2009/043691 WO2009140320A1 (en)	2008-05-13	2009-05-13	Pyrrolopyridines as kinase inhibitors
EP09747404.3A EP2307409B1 (en)	2008-05-13	2009-05-13	Pyrrolopyridines as kinase inhibitors

Publications (1)

Publication Number	Publication Date
HRP20151018T1 true HRP20151018T1 (hr)	2015-10-23

Family

ID=40810786

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HRP20151018TT HRP20151018T1 (hr)	2008-05-13	2015-09-28	Pirolopiridini kao inhibitori kinaze

Country Status (30)

Country	Link
US (6)	US8178131B2 (el)
EP (2)	EP2990407B1 (el)
JP (2)	JP5703212B2 (el)
KR (2)	KR101643426B1 (el)
CN (3)	CN104926810B (el)
AR (1)	AR071717A1 (el)
AU (1)	AU2009246402B2 (el)
BR (1)	BRPI0913580B8 (el)
CA (1)	CA2724262C (el)
CL (1)	CL2009001152A1 (el)
CO (1)	CO6321244A2 (el)
CR (1)	CR11803A (el)
CY (1)	CY1116692T1 (el)
DK (1)	DK2307409T3 (el)
ES (1)	ES2552643T3 (el)
HK (2)	HK1152035A1 (el)
HR (1)	HRP20151018T1 (el)
HU (1)	HUE026160T2 (el)
IL (1)	IL209258A (el)
MX (1)	MX2010012449A (el)
NZ (1)	NZ589318A (el)
PH (1)	PH12013501779A1 (el)
PL (1)	PL2307409T3 (el)
PT (1)	PT2307409E (el)
RS (1)	RS54358B1 (el)
RU (1)	RU2517194C2 (el)
SI (1)	SI2307409T1 (el)
TW (2)	TWI458727B (el)
UA (1)	UA111933C2 (el)
WO (1)	WO2009140320A1 (el)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP5608097B2 (ja)	2008-01-08	2014-10-15	アレイバイオファーマ、インコーポレイテッド	キナーゼ阻害薬としてのピロロピリジン
JP5608098B2 (ja)	2008-01-09	2014-10-15	アレイバイオファーマ、インコーポレイテッド	キナーゼ阻害薬としてのピラゾロピリジン
JP2009256298A (ja) *	2008-03-26	2009-11-05	Sumitomo Chemical Co Ltd	ピペリジン−３−イルカーバメート化合物の光学分割方法およびその中間体
AR071717A1 (es)	2008-05-13	2010-07-07	Array Biopharma Inc	Pirrolo[2,3-b]piridinas inhibidoras de quinasas chk1 y chk2,composiciones farmaceuticas que las contienen,proceso para prepararlas y uso de las mismas en el tratamiento y prevencion del cancer.
MX341368B (es) *	2009-04-11	2016-08-17	Array Biopharma Inc *	Inhibidores de la cinasa del punto de control 1 para potenciar agentes dañinos del adn.
US8481557B2 (en)	2009-04-11	2013-07-09	Array Biopharma Inc.	Method of treatment using checkpoint kinase 1 inhibitors
TWI466885B (zh)	2009-07-31	2015-01-01	Japan Tobacco Inc	含氮螺環化合物及其醫藥用途
WO2011029043A1 (en) *	2009-09-04	2011-03-10	Biogen Idec Ma Inc.	Heteroaryl btk inhibitors
SG187742A1 (en)	2010-08-20	2013-03-28	Hutchison Medipharma Ltd	Pyrrolopyrimidine compounds and uses thereof
EP2640386B1 (en)	2010-11-16	2017-01-18	Array Biopharma Inc.	Combination of checkpoint kinase 1 inhibitors and wee 1 kinase inhibitors
CA2828269C (en)	2011-02-25	2019-01-15	Array Biopharma Inc.	Triazolopyridine compounds as pim kinase inhibitors
MX2013012661A (es)	2011-04-29	2014-03-27	Amgen Inc	Compuestos de piridazina biciclicos como inhibidores pim.
GB201201566D0 (en)	2012-01-30	2012-03-14	Vernalis R&D Ltd	New chemical compounds
MY168958A (en)	2012-04-23	2019-01-28	Genentech Inc	Intermediates and processes for preparing compounds
CN112472699A (zh)	2013-07-26	2021-03-12	种族肿瘤学公司	改善比生群及衍生物的治疗益处的组合方法
MX369174B (es) *	2013-08-22	2019-10-30	Genentech Inc	Proceso para la preparación de un compuesto.
WO2015027090A1 (en) *	2013-08-22	2015-02-26	Genentech, Inc.	Intermediates and processes for preparing compounds
BR112016006388A2 (pt)	2013-09-25	2017-08-01	Vertex Pharma	inibidor seletivo da fosfatidilinositol 3-quinase gama
KR102359214B1 (ko)	2014-04-04	2022-02-07	델 마 파마슈티컬스	폐의 비소세포 암종 및 난소암을 치료하기 위한 디안하이드로갈락티톨 및 이의 유사체 또는 유도체
US9580416B2 (en)	2014-07-02	2017-02-28	Pharmacyclics Llc	Inhibitors of Bruton's tyrosine kinase
MA41599A (fr) *	2015-02-26	2018-01-02	Array Biopharma Inc	Formes cristallines d'un composé pyrrolopyridine
WO2017003090A1 (ko)	2015-06-30	2017-01-05	서울바이오시스 주식회사	Uv led가 적용된 포충기
RS63146B1 (sr)	2015-11-04	2022-05-31	Merck Patent Gmbh	Btk inhibitor za upotrebu u lečenju karcinoma
AU2016378579A1 (en) *	2015-12-22	2018-06-14	Vitae Pharmaceuticals, Inc.	Inhibitors of the menin-MLL interaction
LT3468966T (lt)	2016-06-10	2021-02-25	Vitae Pharmaceuticals, Llc	Menino-mll sąveikos inhibitoriai
EP3461480A1 (en)	2017-09-27	2019-04-03	Onxeo	Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer
US11618749B2 (en)	2018-07-03	2023-04-04	Ifm Due, Inc.	Compounds and compositions for treating conditions associated with STING activity
CN109053526A (zh) *	2018-08-13	2018-12-21	南通大学	一种（3r，4s）-4-甲基吡咯烷-3-基氨基甲酸叔丁酯盐酸盐的化学合成方法
CN108912032A (zh) *	2018-08-13	2018-11-30	南通大学	一种（3s，4r）-4-甲基吡咯烷-3-基氨基甲醇叔丁酯盐酸盐的化学合成方法
WO2020150417A2 (en)	2019-01-17	2020-07-23	Ifm Due, Inc.	Compounds and compositions for treating conditions associated with sting activity
US20230271941A1 (en)	2020-07-15	2023-08-31	Ifm Due, Inc.	Compounds and compositions for treating conditions associated with sting activity
IL308476A (en)	2021-05-14	2024-01-01	Syndax Pharmaceuticals Inc	Inhibitors of the menin-mil interaction

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1995010519A1 (en)	1993-10-14	1995-04-20	Abbott Laboratories	Quinolizinone type compounds
US5543523A (en)	1994-11-15	1996-08-06	Regents Of The University Of Minnesota	Method and intermediates for the synthesis of korupensamines
US6653304B2 (en)	2000-02-11	2003-11-25	Bristol-Myers Squibb Co.	Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators for treating respiratory and non-respiratory diseases
AU2001249865A1 (en)	2000-04-18	2001-10-30	Agouron Pharmaceuticals, Inc.	Pyrazoles for inhibiting protein kinase
WO2003022214A2 (en)	2001-09-06	2003-03-20	Millennium Pharmaceuticals, Inc.	Piperazine and homopiperazine compounds
WO2003028724A1 (en) *	2001-10-04	2003-04-10	Smithkline Beecham Corporation	Chk1 kinase inhibitors
US6797825B2 (en)	2001-12-13	2004-09-28	Abbott Laboratories	Protein kinase inhibitors
TWI329112B (en) *	2002-07-19	2010-08-21	Bristol Myers Squibb Co	Novel inhibitors of kinases
KR20050069977A (ko)	2002-08-07	2005-07-05	미쯔비시 웰 파마 가부시키가이샤	디히드로피라졸로피리딘 화합물
US20050256157A1 (en)	2002-08-23	2005-11-17	Chiron Corporation	Combination therapy with CHK1 inhibitors
US8580782B2 (en)	2002-09-04	2013-11-12	Merck Sharp & Dohme Corp.	Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
AR042667A1 (es)	2002-12-26	2005-06-29	Taisho Pharmaceutical Co Ltd	Derivados de pirrolopirimidina y pirrolopiridina sustituidos con un grupo amino ciclico
US20070149560A1 (en)	2003-03-14	2007-06-28	Astrazeneca Ab	Novel fused triazolones and the uses thereof
GB0308208D0 (en) *	2003-04-09	2003-05-14	Glaxo Group Ltd	Chemical compounds
GB0330043D0 (en) *	2003-12-24	2004-01-28	Pharmacia Italia Spa	Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions comprising them
GB0330042D0 (en) *	2003-12-24	2004-01-28	Pharmacia Italia Spa	Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions them
CA2561724A1 (en) *	2004-04-02	2005-11-03	Vertex Pharmaceuticals Incorporated	Azaindoles useful as inhibitors of rock and other protein kinases
AU2005244745B2 (en) *	2004-04-13	2012-05-03	Synta Pharmaceuticals Corp.	Disalt inhibitors of IL-12 production
GB0409080D0 (en)	2004-04-23	2004-05-26	Biofocus Discovery Ltd	Compounds which interact with protein kinases
JP2007161585A (ja)	2004-06-25	2007-06-28	Taisho Pharmaceut Co Ltd	環状アミノ基で置換されているピロロピリミジン及びピロロピリジン誘導体
UY29177A1 (es)	2004-10-25	2006-05-31	Astex Therapeutics Ltd	Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos
GB0501999D0 (en)	2005-02-01	2005-03-09	Sentinel Oncology Ltd	Pharmaceutical compounds
BRPI0608659A2 (pt)	2005-04-06	2010-11-30	Astrazeneca Ab	composto, métodos para limitar a proliferação celular, de tratamento de um ser humano ou animal sofrendo de uma doença, e de tratamento de profilaxia do cáncer, para tratar cáncer, de tratamento de infecções associadas com cáncer, e de profilaxia de infecções associadas com cáncer, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, métodos para inibir chk1 cinase, e um pak cinase, e para limitar a tumorigênese em um ser humano ou animal, e, processo para a preparação de um composto ou um sal farmaceuticamente aceitável do mesmo
CA2609126A1 (en) *	2005-05-20	2006-11-30	Vertex Pharmaceuticals Incorporated	Pyrrolopyridines useful as inhibitors of protein kinase
WO2007026664A1 (ja) *	2005-08-30	2007-03-08	Asahi Kasei Pharma Corporation	スルホンアミド化合物
EP1931676B1 (en)	2005-10-06	2011-11-16	Schering Corporation	Pyrazolopyrimidines as protein kinase inhibitors
TWI421078B (zh)	2005-10-06	2014-01-01	Merck Sharp & Dohme	關卡激酶抑制劑及其用途
RS58113B1 (sr)	2005-12-13	2019-02-28	Incyte Holdings Corp	Derivati pirolo[2,3-d]pirimidina kao inhibitori janus kinaze
EP1979353A2 (en)	2006-01-19	2008-10-15	OSI Pharmaceuticals, Inc.	Fused heterobicyclic kinase inhibitors
DE102006005180A1 (de)	2006-02-06	2007-08-09	Merck Patent Gmbh	Indazol-heteroaryl-derivate
DE102006005179A1 (de)	2006-02-06	2007-08-09	Merck Patent Gmbh	Aminoindazolderivate
EP2016077A2 (en)	2006-04-25	2009-01-21	Astex Therapeutics Limited	Pharmaceutical compounds
WO2007125321A2 (en) *	2006-04-25	2007-11-08	Astex Therapeutics Limited	Purine and deazapurine derivatives as pharmaceutical compounds
JP2009536620A (ja)	2006-04-25	2009-10-15	アステックス、セラピューティックス、リミテッド	医薬組み合わせ物
WO2008012635A2 (en) *	2006-07-26	2008-01-31	Pfizer Products Inc.	Amine derivatives useful as anticancer agents
WO2008075007A1 (en)	2006-12-21	2008-06-26	Cancer Research Technology Limited	Morpholino-substituted bicycloheteroaryl compounds and their use as anti cancer agents
BRPI0808523A2 (pt)	2007-03-01	2014-08-19	Novartis Vaccines & Diagnostic	Inibidores de pim cinase e métodos de seu uso
WO2009004329A1 (en)	2007-07-02	2009-01-08	Cancer Research Technology Limited	9h-pyrimido[4,5-b]indoles, 9h-pyrido[4',3':4,5]pyrrolo[2,3-d]pyridines, and 9h-1,3,6,9-tetraaza-fluorenes as chk1 kinase function inhibitors
CA2705092A1 (en)	2007-11-07	2009-05-14	Schering Corporation	Novel modulators of cell cycle checkpoints and their use in combination with checkpoint kinase inhibitors
JP5608097B2 (ja)	2008-01-08	2014-10-15	アレイバイオファーマ、インコーポレイテッド	キナーゼ阻害薬としてのピロロピリジン
JP5608098B2 (ja)	2008-01-09	2014-10-15	アレイバイオファーマ、インコーポレイテッド	キナーゼ阻害薬としてのピラゾロピリジン
AR071717A1 (es) *	2008-05-13	2010-07-07	Array Biopharma Inc	Pirrolo[2,3-b]piridinas inhibidoras de quinasas chk1 y chk2,composiciones farmaceuticas que las contienen,proceso para prepararlas y uso de las mismas en el tratamiento y prevencion del cancer.
US8481557B2 (en) *	2009-04-11	2013-07-09	Array Biopharma Inc.	Method of treatment using checkpoint kinase 1 inhibitors
US20140221370A1 (en)	2010-07-09	2014-08-07	Array Biopharma Inc.	Pyrrolopyridines as kinase inhibitors
EP2640386B1 (en)	2010-11-16	2017-01-18	Array Biopharma Inc.	Combination of checkpoint kinase 1 inhibitors and wee 1 kinase inhibitors

2009
- 2009-05-12 AR ARP090101708A patent/AR071717A1/es active IP Right Grant
- 2009-05-12 CL CL2009001152A patent/CL2009001152A1/es unknown
- 2009-05-13 RS RS20150711A patent/RS54358B1/en unknown
- 2009-05-13 DK DK09747404.3T patent/DK2307409T3/en active
- 2009-05-13 ES ES09747404.3T patent/ES2552643T3/es active Active
- 2009-05-13 CN CN201510289964.7A patent/CN104926810B/zh active Active
- 2009-05-13 BR BRPI0913580A patent/BRPI0913580B8/pt not_active IP Right Cessation
- 2009-05-13 CN CN200980127299.4A patent/CN102089307B/zh active Active
- 2009-05-13 MX MX2010012449A patent/MX2010012449A/es active IP Right Grant
- 2009-05-13 WO PCT/US2009/043691 patent/WO2009140320A1/en active Application Filing
- 2009-05-13 AU AU2009246402A patent/AU2009246402B2/en not_active Ceased
- 2009-05-13 CN CN201910068067.1A patent/CN109942575A/zh active Pending
- 2009-05-13 RU RU2010150786/04A patent/RU2517194C2/ru active
- 2009-05-13 TW TW098115906A patent/TWI458727B/zh active
- 2009-05-13 HU HUE09747404A patent/HUE026160T2/en unknown
- 2009-05-13 PL PL09747404T patent/PL2307409T3/pl unknown
- 2009-05-13 EP EP15175131.0A patent/EP2990407B1/en active Active
- 2009-05-13 EP EP09747404.3A patent/EP2307409B1/en active Active
- 2009-05-13 NZ NZ589318A patent/NZ589318A/en not_active IP Right Cessation
- 2009-05-13 UA UAA201015012A patent/UA111933C2/uk unknown
- 2009-05-13 US US12/992,468 patent/US8178131B2/en active Active
- 2009-05-13 KR KR1020107027941A patent/KR101643426B1/ko active IP Right Grant
- 2009-05-13 TW TW103133772A patent/TWI554512B/zh active
- 2009-05-13 SI SI200931284T patent/SI2307409T1/sl unknown
- 2009-05-13 KR KR1020147015705A patent/KR101657856B1/ko active IP Right Grant
- 2009-05-13 CA CA2724262A patent/CA2724262C/en active Active
- 2009-05-13 JP JP2011509628A patent/JP5703212B2/ja not_active Expired - Fee Related
- 2009-05-13 PT PT97474043T patent/PT2307409E/pt unknown
2010
- 2010-11-11 IL IL209258A patent/IL209258A/en active IP Right Grant
- 2010-11-19 CR CR11803A patent/CR11803A/es unknown
- 2010-11-30 CO CO10150963A patent/CO6321244A2/es active IP Right Grant
2011
- 2011-06-14 HK HK11106054.7A patent/HK1152035A1/xx not_active IP Right Cessation
2012
- 2012-03-20 US US13/425,186 patent/US8545897B2/en active Active
2013
- 2013-08-23 US US13/974,895 patent/US8758830B2/en active Active
- 2013-08-28 PH PH12013501779A patent/PH12013501779A1/en unknown
2014
- 2014-05-06 US US14/271,129 patent/US8981085B2/en active Active
2015
- 2015-01-07 US US14/591,691 patent/US9365568B2/en active Active
- 2015-02-23 JP JP2015032474A patent/JP2015098482A/ja not_active Withdrawn
- 2015-09-16 CY CY20151100812T patent/CY1116692T1/el unknown
- 2015-09-28 HR HRP20151018TT patent/HRP20151018T1/hr unknown
2016
- 2016-01-05 US US14/988,521 patent/US9969727B2/en active Active
- 2016-07-08 HK HK16107983.6A patent/HK1219950A1/zh unknown

Also Published As

Publication number	Publication date
IL209258A0 (en)	2011-01-31
KR20110008102A (ko)	2011-01-25
BRPI0913580B1 (pt)	2020-03-10
JP2015098482A (ja)	2015-05-28
US20110070317A1 (en)	2011-03-24
TW201002707A (en)	2010-01-16
CN104926810A (zh)	2015-09-23
AR071717A1 (es)	2010-07-07
RS54358B1 (en)	2016-04-28
US8981085B2 (en)	2015-03-17
AU2009246402A1 (en)	2009-11-19
CY1116692T1 (el)	2017-03-15
PH12013501779B1 (en)	2014-08-27
US20160368916A1 (en)	2016-12-22
AU2009246402B2 (en)	2013-05-23
US8758830B2 (en)	2014-06-24
RU2517194C2 (ru)	2014-05-27
CA2724262C (en)	2017-08-15
TWI554512B (zh)	2016-10-21
HK1219950A1 (zh)	2017-04-21
TW201529573A (zh)	2015-08-01
SI2307409T1 (sl)	2015-11-30
KR20140093266A (ko)	2014-07-25
CN104926810B (zh)	2019-02-19
CR11803A (es)	2011-02-11
JP5703212B2 (ja)	2015-04-15
JP2011520896A (ja)	2011-07-21
NZ589318A (en)	2011-06-30
CN102089307A (zh)	2011-06-08
US20140100369A1 (en)	2014-04-10
MX2010012449A (es)	2011-05-25
BRPI0913580A2 (pt)	2015-10-20
PT2307409E (pt)	2015-11-04
US20130045286A1 (en)	2013-02-21
PH12013501779A1 (en)	2014-08-27
US9969727B2 (en)	2018-05-15
WO2009140320A1 (en)	2009-11-19
DK2307409T3 (en)	2015-09-21
EP2307409A1 (en)	2011-04-13
RU2010150786A (ru)	2012-06-20
UA111933C2 (uk)	2016-07-11
CN109942575A (zh)	2019-06-28
TWI458727B (zh)	2014-11-01
US20150322061A1 (en)	2015-11-12
CA2724262A1 (en)	2009-11-19
CN102089307B (zh)	2015-07-01
HK1152035A1 (en)	2012-02-17
PL2307409T3 (pl)	2016-01-29
US8545897B2 (en)	2013-10-01
CL2009001152A1 (es)	2009-10-16
KR101643426B1 (ko)	2016-07-27
US9365568B2 (en)	2016-06-14
HUE026160T2 (en)	2016-05-30
BRPI0913580B8 (pt)	2021-05-25
IL209258A (en)	2017-01-31
EP2307409B1 (en)	2015-08-12
EP2990407B1 (en)	2019-10-16
ES2552643T3 (es)	2015-12-01
US20140243520A1 (en)	2014-08-28
US8178131B2 (en)	2012-05-15
EP2990407A1 (en)	2016-03-02
CO6321244A2 (es)	2011-09-20
KR101657856B1 (ko)	2016-09-19

Publication	Publication Date	Title
HRP20151018T1 (hr)	2015-10-23	Pirolopiridini kao inhibitori kinaze
HRP20201469T1 (hr)	2020-12-11	Derivati tetrahidroizokinolina
RU2011107437A (ru)	2012-09-10	Ингибиторы кинуренин-3-моноксигеназы
DK3183247T3 (en)	2018-01-15	Aminopyrimidinyl compounds as JAK inhibitors
JP2021502356A5 (el)	2021-12-09
HRP20210791T2 (hr)	2021-12-10	1-cijano-pirolidin spojevi kao usp30 inhibitori
HRP20181017T1 (hr)	2018-08-24	Heterociklični spojevi i postupci uporabe
JP2012525395A5 (el)	2013-06-13
HRP20180546T1 (hr)	2018-05-04	Supstituirani benzilindazoli za uporabu kao inhibitori bub1 kinaze za liječenje hiperproliferativnih bolesti
JP2016523911A5 (el)	2017-08-03
HRP20170119T1 (hr)	2017-03-24	Novi derivati pirimidina, njihovo pripremanje, te njihova farmaceutska uporaba kao inhibitora akt (pkb) fosforilacije
JP2018512381A5 (el)	2019-04-11
PE20090493A1 (es)	2009-05-27	DERIVADOS DE LA 6-CICLOAMINO-3-(PIRIDAZIN-4-IL)IMIDAZO[1,2-b]-PIRIDAZINA, SU PREPARACION Y SU APLICACION EN TERAPEUTICA
JP2016500073A5 (el)	2016-12-28
RU2018142987A (ru)	2020-07-22	Положительные аллостерические модуляторы мускаринового ацетилхолинового рецептора m4
HRP20201430T1 (hr)	2020-11-27	Spojevi 6-heterociklil-4-morfolin-4-ilpiridin-2-ona korisni za liječenje karcinoma i dijabetesa
RU2016102137A (ru)	2017-07-31	Первичные карбоксамиды в качестве ингибиторов bik
RU2014139601A (ru)	2016-04-20	Ингибиторы серин/треониновых киназ
NZ630467A (en)	2017-02-24	Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
RU2009140149A (ru)	2011-05-10	Пиримидингидразидные соединения как ингибиторы pgds
HRP20160635T1 (hr)	2016-07-01	Inhibitori pirimidina pde10
JP2010510319A5 (el)	2011-01-13
JP2017500364A5 (el)	2019-01-24
RU2012105284A (ru)	2013-08-20	Спиро-аминосоединения, пригодные для лечения нарушений сна и лекарственного привыкания
HRP20120251T1 (hr)	2012-07-31	Derivati benzotiazol ciklobutil amina i njihova uporaba kao liganda receptora histamin